Transcode Therapeutics Q1 2025 10-Q Filed
Ticker: RNAZ · Form: 10-Q · Filed: May 14, 2025 · CIK: 1829635
Sentiment: neutral
Topics: 10-Q, financials, warrants
TL;DR
Transcode Therapeutics Q1 2025 10-Q: Assets $1.03M, Liabilities $2.33M. Warrant adjustments and offerings noted.
AI Summary
Transcode Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported total assets of $1,029,095 and total liabilities of $2,334,133. Key financial activities include fair value adjustments for warrants and significant cash flows related to registered direct offerings and placement agent warrants.
Why It Matters
This filing provides a snapshot of Transcode Therapeutics' financial health and operational activities for the first quarter of 2025, crucial for investors assessing the company's current standing.
Risk Assessment
Risk Level: medium — The company has more liabilities than assets, indicating potential financial strain.
Key Numbers
- $1.03M — Total Assets (As of March 31, 2025)
- $2.33M — Total Liabilities (As of March 31, 2025)
- 20250331 — Reporting Period End Date (Indicates the timeframe covered by the financial statements)
Key Players & Entities
- Transcode Therapeutics, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of reporting period
- 1029095 (dollar_amount) — Total assets
- 23341336 (dollar_amount) — Total liabilities
- 2025-03-31 (date) — Specific date for financial measurements
FAQ
What was the net loss for the quarter ending March 31, 2025?
The provided excerpt does not contain information on the net loss for the quarter ending March 31, 2025.
What is the company's cash position as of March 31, 2025?
The provided excerpt does not explicitly state the company's cash position as of March 31, 2025, though total assets are listed as $1,029,095.
What are the significant warrant-related activities mentioned in the filing?
The filing mentions fair value adjustments for warrants, including those from registered direct offerings and placement agents, with specific dates like March 2025 and June 2023.
What is the company's primary business sector?
Transcode Therapeutics, Inc. is in the Pharmaceutical Preparations sector, SIC code 2834.
What was the filing date for this 10-Q report?
This 10-Q report was filed on May 14, 2025.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding Transcode Therapeutics, Inc. (RNAZ).